Skip to main content

Leadership

News Release

Printer Friendly Version View printer-friendly version
<< Back
Emergent BioSolutions Announces Results from Annual Meeting of Stockholders

ROCKVILLE, Md.--(BUSINESS WIRE)--June 14, 2007--Emergent BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company, announced today the results of the company's 2007 annual meeting of stockholders, which took place today at the Hyatt Regency Bethesda at 10:00 am Eastern.

There were present, in person or represented by proxy, the holders of more than a majority of the shares of the outstanding common stock of the company, thus constituting a quorum.

Proposal 1--Election of Directors

The following individuals were elected Class I directors of the company to serve for a three-year term expiring 2010: Fuad El-Hibri, Jerome M. Hauer and Ronald B. Richard.

Proposal 2--Ratify Selection of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm

The proposal to select Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2007 successfully passed.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission--to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Our biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Our marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Our commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. More information on the company is available at www.emergentbiosolutions.com.

CONTACT: Emergent BioSolutions Inc.
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
burrowsr@ebsi.com

SOURCE: Emergent BioSolutions Inc.